NO20052496L - Selected CGRP antagonists, methods for their preparation and use thereof as drugs. - Google Patents
Selected CGRP antagonists, methods for their preparation and use thereof as drugs.Info
- Publication number
- NO20052496L NO20052496L NO20052496A NO20052496A NO20052496L NO 20052496 L NO20052496 L NO 20052496L NO 20052496 A NO20052496 A NO 20052496A NO 20052496 A NO20052496 A NO 20052496A NO 20052496 L NO20052496 L NO 20052496L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- drugs
- methods
- cgrp antagonists
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Foreliggende oppfinnelse angår CGRP-antagonister med den generelle formel (I) hvor A, U, V, W, X og R1 til R3 er definert som i krav 1, tautomerer, diastereomerer, enantiomerer, hydrater, blandinger derav og saltene derav så vel som hydrater av saltene, spesielt de fysiologisk akseptable salter derav med uorganiske eller organiske syrer, farmasøytiske preparater inneholdende disse forbindelser, anvendelse derav og fremgangsmåter for fremstilling av dem.The present invention relates to CGRP antagonists of general formula (I) wherein A, U, V, W, X and R 1 to R 3 are defined as in claim 1, tautomers, diastereomers, enantiomers, hydrates, mixtures thereof and the salts thereof as well as hydrates of the salts, especially the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, their use and processes for their preparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10250080A DE10250080A1 (en) | 2002-10-25 | 2002-10-25 | Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals |
PCT/EP2003/011762 WO2004037810A1 (en) | 2002-10-25 | 2003-10-23 | Selected cgrp antagonists, method for production and use thereof as medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052496D0 NO20052496D0 (en) | 2005-05-24 |
NO20052496L true NO20052496L (en) | 2005-06-24 |
Family
ID=32103086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052496A NO20052496L (en) | 2002-10-25 | 2005-05-24 | Selected CGRP antagonists, methods for their preparation and use thereof as drugs. |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1558600B1 (en) |
JP (1) | JP4401296B2 (en) |
KR (1) | KR20050074970A (en) |
CN (1) | CN1708493A (en) |
AR (1) | AR041718A1 (en) |
AT (1) | ATE394392T1 (en) |
AU (1) | AU2003276156A1 (en) |
BR (1) | BR0315665A (en) |
CA (1) | CA2503455A1 (en) |
CO (1) | CO5570704A2 (en) |
DE (2) | DE10250080A1 (en) |
DK (1) | DK1558600T3 (en) |
EA (1) | EA009219B1 (en) |
EC (1) | ECSP055747A (en) |
ES (1) | ES2306918T3 (en) |
HR (1) | HRP20050364A2 (en) |
IL (1) | IL168056A0 (en) |
MX (1) | MXPA05004375A (en) |
NO (1) | NO20052496L (en) |
PE (1) | PE20040592A1 (en) |
PL (1) | PL376450A1 (en) |
RS (1) | RS20050311A (en) |
TW (1) | TW200413317A (en) |
UA (1) | UA79323C2 (en) |
UY (1) | UY28034A1 (en) |
WO (1) | WO2004037810A1 (en) |
ZA (1) | ZA200502248B (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19963868A1 (en) * | 1999-12-30 | 2001-07-12 | Boehringer Ingelheim Pharma | New substituted piperidines, pharmaceutical compositions containing these compounds and process for their preparation |
CN1293042C (en) * | 2002-02-07 | 2007-01-03 | 远藤仁 | Aromatic amino acid derivates and medicinal compositions |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
WO2005004869A1 (en) * | 2003-07-07 | 2005-01-20 | Boehringer Ingelheim International Gmbh | Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
DE102004015723A1 (en) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
DE102004018795A1 (en) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals |
DE102004018796A1 (en) * | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals |
US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
ATE537153T1 (en) * | 2004-09-09 | 2011-12-15 | Merck Sharp & Dohme | ARYLSPIROLACTAM COMPOUNDS AS ANTAGONISTS OF THE CGRP RECEPTOR |
US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
DE102004063752A1 (en) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of selected CGRP antagonists to combat menopausal hot flashes |
DE102004063753A1 (en) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of selected CGRP antagonists in combination with other migraine medicines for the treatment of migraine |
DE102004063755A1 (en) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of CGRP antagonists for the treatment and prevention of hot flushes in patients with prostate cancer |
CN101146799A (en) * | 2005-03-23 | 2008-03-19 | 贝林格尔·英格海姆国际有限公司 | Cgrp-antagonists, process for their preparation as well as their use as medicaments |
EP1770091A1 (en) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-antagonists, process for their preparation as well as their use as medicaments |
US7491717B2 (en) | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7439237B2 (en) | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (en) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New N-acylalkoxycarbonyl-piperidine derivatives, useful as CGRP antagonists, for treating e.g. headaches, cardiovascular disease, skin disorders, morphine tolerance, and inflammatory diseases such as osteoarthritis and allergic rhinitis |
US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
EP1770087A1 (en) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Selected CGRP antagonists, process for their preparation as well as their use as medicaments |
EP1770086A1 (en) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Selected CGRP antagonists, process for their preparation as well as their use as medicaments |
DE102005050892A1 (en) | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals |
DE102006017827A1 (en) | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New crystalline compounds |
PE20080153A1 (en) | 2006-06-08 | 2008-04-14 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION INCLUDING AN ANTAGONIST OF THE PEPTIDE RELATED TO THE CALCITONIN GENE (CGRP) |
DE102007038250A1 (en) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New manufacturing process |
BRPI0817835A2 (en) | 2007-10-18 | 2015-03-31 | Boehringer Ingelheim Int | CGRP ANTAGONISTS |
EP2065381A1 (en) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP antagonists |
EP2225223B1 (en) | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organic compounds |
US8633228B2 (en) | 2008-08-01 | 2014-01-21 | Mitsui Chemicals Agro, Inc. | Amide derivative, pest control agent containing the amide derivative, and pest controlling method |
PT2396081T (en) | 2009-02-16 | 2017-07-11 | Nogra Pharma Ltd | Alkylamido compounds and uses thereof |
CA2864059C (en) | 2012-02-09 | 2020-04-28 | Nogra Pharma Limited | Methods of treating fibrosis |
EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
LT3668853T (en) | 2017-08-16 | 2022-03-10 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
CN111801330B (en) | 2018-01-26 | 2024-04-05 | 盐野义制药株式会社 | Fused ring compounds having dopamine D3 receptor antagonism |
EA202192207A1 (en) | 2019-02-08 | 2021-10-27 | Ногра Фарма Лимитед | METHOD FOR OBTAINING 3- (4'-AMINOPHENYL) -2-METHOXYPROPIONIC ACID AND ITS ANALOGUES AND INTERMEDIATE COMPOUNDS |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2345357A1 (en) * | 1998-09-30 | 2000-04-06 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
DE19937304C2 (en) * | 1999-08-10 | 2003-08-21 | Boehringer Ingelheim Pharma | Use of CGRP antagonists to combat menopausal hot flashes |
-
2002
- 2002-10-25 DE DE10250080A patent/DE10250080A1/en not_active Withdrawn
-
2003
- 2003-10-22 UY UY28034A patent/UY28034A1/en not_active Application Discontinuation
- 2003-10-23 PL PL03376450A patent/PL376450A1/en not_active Application Discontinuation
- 2003-10-23 CA CA002503455A patent/CA2503455A1/en not_active Abandoned
- 2003-10-23 KR KR1020057007144A patent/KR20050074970A/en not_active Application Discontinuation
- 2003-10-23 MX MXPA05004375A patent/MXPA05004375A/en not_active Application Discontinuation
- 2003-10-23 UA UAA200504872A patent/UA79323C2/en unknown
- 2003-10-23 AT AT03809317T patent/ATE394392T1/en active
- 2003-10-23 CN CNA2003801020040A patent/CN1708493A/en active Pending
- 2003-10-23 WO PCT/EP2003/011762 patent/WO2004037810A1/en active IP Right Grant
- 2003-10-23 AU AU2003276156A patent/AU2003276156A1/en not_active Abandoned
- 2003-10-23 BR BR0315665-6A patent/BR0315665A/en not_active Expired - Fee Related
- 2003-10-23 JP JP2004545963A patent/JP4401296B2/en not_active Expired - Fee Related
- 2003-10-23 DE DE50309807T patent/DE50309807D1/en not_active Expired - Lifetime
- 2003-10-23 ES ES03809317T patent/ES2306918T3/en not_active Expired - Lifetime
- 2003-10-23 DK DK03809317T patent/DK1558600T3/en active
- 2003-10-23 EP EP03809317A patent/EP1558600B1/en not_active Expired - Lifetime
- 2003-10-23 PE PE2003001077A patent/PE20040592A1/en not_active Application Discontinuation
- 2003-10-23 RS YUP-2005/0311A patent/RS20050311A/en unknown
- 2003-10-23 EA EA200500600A patent/EA009219B1/en not_active IP Right Cessation
- 2003-10-24 TW TW092129640A patent/TW200413317A/en unknown
- 2003-10-24 AR ARP030103889A patent/AR041718A1/en unknown
-
2005
- 2005-03-17 ZA ZA200502248A patent/ZA200502248B/en unknown
- 2005-04-14 IL IL168056A patent/IL168056A0/en unknown
- 2005-04-22 HR HR20050364A patent/HRP20050364A2/en not_active Application Discontinuation
- 2005-04-25 EC EC2005005747A patent/ECSP055747A/en unknown
- 2005-05-24 NO NO20052496A patent/NO20052496L/en not_active Application Discontinuation
- 2005-05-24 CO CO05050511A patent/CO5570704A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HRP20050364A2 (en) | 2006-05-31 |
AR041718A1 (en) | 2005-05-26 |
IL168056A0 (en) | 2009-02-11 |
EP1558600B1 (en) | 2008-05-07 |
WO2004037810A1 (en) | 2004-05-06 |
DK1558600T3 (en) | 2008-09-01 |
CO5570704A2 (en) | 2005-10-31 |
NO20052496D0 (en) | 2005-05-24 |
BR0315665A (en) | 2005-08-30 |
EA200500600A1 (en) | 2006-02-24 |
EA009219B1 (en) | 2007-12-28 |
CA2503455A1 (en) | 2004-05-06 |
JP4401296B2 (en) | 2010-01-20 |
EP1558600A1 (en) | 2005-08-03 |
ZA200502248B (en) | 2006-08-30 |
PL376450A1 (en) | 2005-12-27 |
PE20040592A1 (en) | 2004-10-27 |
CN1708493A (en) | 2005-12-14 |
DE50309807D1 (en) | 2008-06-19 |
KR20050074970A (en) | 2005-07-19 |
JP2006516244A (en) | 2006-06-29 |
UY28034A1 (en) | 2004-05-31 |
MXPA05004375A (en) | 2005-07-05 |
ECSP055747A (en) | 2005-07-06 |
UA79323C2 (en) | 2007-06-11 |
RS20050311A (en) | 2007-08-03 |
TW200413317A (en) | 2004-08-01 |
AU2003276156A1 (en) | 2004-05-13 |
ES2306918T3 (en) | 2008-11-16 |
ATE394392T1 (en) | 2008-05-15 |
DE10250080A1 (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052496L (en) | Selected CGRP antagonists, methods for their preparation and use thereof as drugs. | |
NO20052493L (en) | Selected CGRP antagonists, processes for their preparation and their use as pharmaceutical compositions. | |
NO20064166L (en) | Selected CGRP antagonists, their preparation and their use as medicaments | |
TW200606151A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
NO20062713L (en) | 2.6 bis-heteroaryl-4-aminopyrimidines as adenosine receptor antagonists | |
TW200603799A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
NO20023161L (en) | Substituted piperidines, drugs containing these compounds and processes for their preparation | |
NO20044826L (en) | pyrrolidine | |
NO20061839L (en) | Benzimidazole derivatives, compositions containing them, their preparation, and their use | |
WO2002098856A3 (en) | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists | |
NO20060146L (en) | Benzimidazole derivatives, compositions containing them, their preparation and their use | |
NO20060147L (en) | Benzimidazole derivatives, compositions containing them, their preparation and their use | |
NO20060195L (en) | Quinolylamide derivatives as CCR-5 antagonists | |
NO20070432L (en) | Pyrimidine urea derivatives as kinase inhibitors | |
NO20071137L (en) | New piperidine derivatives for the treatment of depression | |
NO20054787D0 (en) | Indene derivatives as pharmaceuticals | |
NO20052683L (en) | New pyridopyrimidinone compounds, processes for their preparation and pharmaceutical compositions containing them | |
ECSP045378A (en) | NEW DIAZABICICLONONENE DERIVATIVES | |
NO20045486L (en) | New compounds and their use | |
NO20062491L (en) | Benzoxazine derivatives and their use | |
NO20076680L (en) | Selected CGRP antagonists, methods for their preparation and their use as drugs | |
NO20070837L (en) | Pyrido-pyrido pyrimidine derivatives, their preparation and therapeutic application for the treatment of cancer. | |
WO2004014869A3 (en) | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | |
YU30902A (en) | Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof | |
NO20040881L (en) | Oral antidiabetic agents. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |